Wuxi Biologics has reported a full-year net income of 3.40 billion yuan, falling short of the estimated 3.58 billion yuan. The company’s revenue exceeded estimates, coming in at 17.03 billion yuan against an estimated 16.98 billion yuan. Adjusted net income surpassed estimates, with Wuxi Biologics reporting 4.70 billion yuan against an estimated 4.2 billion yuan. The gross margin for the c...
$药明康德(02359.HK)$closed up by 5.7% and$药明生物(02269.HK)$rose by 7.5% in Hong Kong on Monday after the departure of Mike Gallagher, chairman of the House Select Committee on the Chinese Communist Party, which could slow the legislation’s progress of the Biosecure Act. $恒生中国企业(02828.HK)$$恒生指数(800000.HK)$
Peter YCS楼主 : 我在美国市场买入,香港这专业割投资人韭菜……美国市场可能少量买入在看它是否跌落在哪……香港一手就要500股一手,太狠了,不如投药明康德,一手100股,还有股息……
Gancongyap : Need to be careful this stock… cos US big player going to ban this stock … due to human gene… US similar banned HuaWei
103115047 : 無知是很可怕的
總有一天等到你 : 有提到還可以買嗎
trend investor : 今天又新低了
查看更多评论...